27 December 2024
Intelligent Ultrasound Group
plc
("Intelligent Ultrasound" or the "Group" or the
"Company")
Exercise of Options, Total
Voting Rights and Rule 2.9 Announcement
Intelligent Ultrasound Group plc
(AIM: IUG), the ultrasound simulation and education company,
announces that it has issued, conditional on admission, 3,823,182
new ordinary shares of 1 pence each in the capital of the Company
("Ordinary Shares"), pursuant to the exercise of share
options.
The new Ordinary Shares will rank
pari passu with the existing Ordinary Shares in issue and
application has been made for the new Ordinary Shares to be
admitted to trading on the AIM Market of the London Stock Exchange
("Admission"). Admission is expected to occur, and dealings in the
new Ordinary Shares commence, at 8:00 a.m. on 31 December
2024.
Rule 2.9 Announcement and Total Voting
Rights
Following Admission,
in accordance with Rule 2.9 of the City Code on
Takeovers and Mergers (the "Code"), the Company will have
331,013,103 Ordinary Shares in issue. This figure of 331,013,103
may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change of their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
ENDS
For further information, please
contact:
Intelligent Ultrasound
|
+44 (0)29 2075 6534
|
Stuart Gall, CEO
Helen Jones, CFO
|
|
Cavendish Capital Markets Limited (Rule 3 Independent
Financial Adviser, Nominated Adviser and Corporate Broker to
Intelligent Ultrasound)
|
|
Giles Balleny
Henrik Persson
Hamish Waller
|
+44 (0) 20 7220 0500
|
Cardew Group (PR Adviser to Intelligent
Ultrasound)
|
|
Alison Connolly
|
+44 (0) 7587 453955
|
Emma Pascoe-Watson
|
+44 (0) 7774 620415
|
Jessica Pilling
|
+44 (0) 7918 584573
|
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM:
IUG) is one of the world's leading ultrasound simulation and
education companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market. The
company's main products are the ScanTrainer obstetrics
and gynaecology training simulator,
the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency
Medicine training simulator, the new BabyWorks Neonate and
Paediatric training simulator and NeedleTrainer, which teaches
real-time ultrasound-guided needling. To date over 1,800
simulators have been sold to over 800 medical
institutions around the world.
www.intelligentultrasound.com
This announcement does not
constitute an offer to purchase any securities, or an offer to sell
or the solicitation of an offer to buy any securities, nor shall
there be any offer to purchase or sell securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful. The release, distribution or publication of this
announcement in jurisdictions other than the UK may be restricted
by law and therefore any persons who are subject to the laws of any
jurisdiction other than the UK should inform themselves about and
observe any applicable requirements.
Disclosure requirements of the Code
Under Rule 8.3(a) of the Code, any
person who is interested in 1% or more of any class of relevant
securities of an offeree company or of any securities exchange
offeror (being any offeror other than an offeror in respect of
which it has been announced that its offer is, or is likely to be,
solely in cash) must make an Opening Position Disclosure (as
defined in the Code) following the commencement of the offer period
and, if later, following the announcement in which any securities
exchange offeror is first identified. An Opening Position
Disclosure must contain details of the person's interests and short
positions in, and rights to subscribe for, any relevant securities
of each of (i) the offeree company and (ii) any securities exchange
offeror(s). An Opening Position Disclosure by a person to whom Rule
8.3(a) applies must be made by no later than 3.30 p.m. (London
time) on the 10th business day following the commencement of the
offer period and, if appropriate, by no later than 3.30 p.m.
(London time) on the 10th business day following the announcement
in which any securities exchange offeror is first identified.
Relevant persons who deal in the relevant securities of the offeree
company or of a securities exchange offeror prior to the deadline
for making an Opening Position Disclosure must instead make a
Dealing Disclosure (as defined in the Code).
Under Rule 8.3(b) of the Code, any
person who is, or becomes, interested in 1% or more of any class of
relevant securities of the offeree company or of any securities
exchange offeror must make a Dealing Disclosure if the person deals
in any relevant securities of the offeree company or of any
securities exchange offeror. A Dealing Disclosure must contain
details of the dealing concerned and of the person's interests and
short positions in, and rights to subscribe for, any relevant
securities of each of (i) the offeree company and (ii) any
securities exchange offeror(s), save to the extent that these
details have previously been disclosed under Rule 8. A Dealing
Disclosure by a person to whom Rule 8.3(b) applies must be made by
no later than 3.30 p.m. (London time) on the business day following
the date of the relevant dealing.
If two or more persons act together
pursuant to an agreement or understanding, whether formal or
informal, to acquire or control an interest in relevant securities
of an offeree company or a securities exchange offeror, they will
be deemed to be a single person for the purpose of Rule
8.3.
Opening Position Disclosures must
also be made by the offeree company and by any offeror and Dealing
Disclosures must also be made by the offeree company, by any
offeror and by any persons acting in concert with any of them (see
Rules 8.1, 8.2 and 8.4).
Details of the offeree and Bidder
companies in respect of whose relevant securities Opening Position
Disclosures and Dealing Disclosures must be made can be found in
the Disclosure Table on the Takeover Panel's website at
www.thetakeoverpanel.org.uk, including details of the number of
relevant securities in issue, when the offer period commenced and
when any Bidder was first identified. You should contact the
Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are
in any doubt as to whether you are required to make an Opening
Position Disclosure or a Dealing Disclosure.